drugset / Trial / NCT05814848
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of post-marketing Regiorense injection secondary infusion in the treatment of adult patients with relapsed or refractory B-cell lymphoma.
Timeline
- Start
- 2023-06-20
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relmacabtagene Autoleucel | Cell therapy | — | — |